ATE151634T1 - Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält - Google Patents

Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält

Info

Publication number: ATE151634T1
Authority: AT; Austria
Prior art keywords: guanidinopropionic acid; pct; insulin; provides; drugs
Prior art date: 1991-08-26

Application number

AT92918163T

Other languages

English (en)

Inventor

Martin Durham Meglasson

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-26

Filing date

1992-08-19

Publication date

1997-05-15

1991-08-26 Priority claimed from US07/751,239 external-priority patent/US6008253A/en

1992-08-19 Application filed by Upjohn Co filed Critical Upjohn Co

1997-05-15 Application granted granted Critical

1997-05-15 Publication of ATE151634T1 publication Critical patent/ATE151634T1/de

Links

KMXXSJLYVJEBHI-UHFFFAOYSA-N 3-guanidinopropanoic acid Chemical compound NC(=[NH2+])NCCC([O-])=O KMXXSJLYVJEBHI-UHFFFAOYSA-N 0.000 title abstract 5
235000021056 liquid food Nutrition 0.000 title 1
229940079593 drug Drugs 0.000 abstract 4
239000003814 drug Substances 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
235000013305 food Nutrition 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
230000003914 insulin secretion Effects 0.000 abstract 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
230000001235 sensitizing effect Effects 0.000 abstract 2
230000004936 stimulating effect Effects 0.000 abstract 2
208000008589 Obesity Diseases 0.000 abstract 1
GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
229940127003 anti-diabetic drug Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229960004580 glibenclamide Drugs 0.000 abstract 1
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
229960004346 glimepiride Drugs 0.000 abstract 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
229960002827 pioglitazone hydrochloride Drugs 0.000 abstract 1
230000007103 stamina Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

AT92918163T 1991-08-26 1992-08-19 Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält ATE151634T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US75055991A	1991-08-26	1991-08-26
US07/751,239 US6008253A (en)	1991-08-26	1991-08-26	Use of 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity in a mammal

Publications (1)

Publication Number	Publication Date
ATE151634T1 true ATE151634T1 (de)	1997-05-15

Family

ID=27115296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92918163T ATE151634T1 (de)	1991-08-26	1992-08-19	Flüssiges nahrungsmittel, das 3- guanidinopropionsäure enthält

Country Status (10)

Country	Link
US (1)	US5900435A (de)
EP (1)	EP0601001B1 (de)
JP (1)	JPH06510286A (de)
AT (1)	ATE151634T1 (de)
AU (1)	AU2479492A (de)
DE (1)	DE69219136T2 (de)
DK (1)	DK0601001T3 (de)
ES (1)	ES2101866T3 (de)
GR (1)	GR3023848T3 (de)
WO (1)	WO1993003724A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7316591A (en) *	1990-02-28	1991-09-18	Upjohn Company, The	Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
AU3117497A (en) *	1996-05-21	1997-12-09	Pharmacia & Upjohn Company	Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
CA2260044A1 (en) *	1996-07-12	1998-01-22	Stephen Alistair Smith	Novel treatment of leptine resistance
DE69738809D1 (de) *	1996-11-08	2008-08-14	Nippon Chemiphar Co	Mittel zur verringerung der eigeweidefette
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
BR9810142A (pt) *	1997-06-18	2000-08-08	Smithkline Beecham Plc	Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
KR20060105005A (ko) *	1997-06-18	2006-10-09	스미스클라인비이참피이엘시이	티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) *	1997-06-18	2001-12-06	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and sulphonylurea
AP9901720A0 (en) *	1997-06-18	1999-12-31	Smithkline Beecham Plc	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
GB9715295D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
GB9715306D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
US20020016287A1 (en) *	1997-07-18	2002-02-07	Smithkline Beecham P.L.C.	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715298D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
AR019727A1 (es)	1998-06-30	2002-03-13	Takeda Chemical Industries Ltd	Composicion farmaceutica
US20040102486A1 (en) *	1998-11-12	2004-05-27	Smithkline Beecham Corporation	Novel method of treatment
GB9824893D0 (en) *	1998-11-12	1999-01-06	Smithkline Beckman Corp	Novel method of treatment
US6667064B2 (en) *	2000-08-30	2003-12-23	Pilot Therapeutics, Inc.	Composition and method for treatment of hypertriglyceridemia
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7504118B2 (en) *	2003-04-11	2009-03-17	Fhg Corporation	Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
EP1868453A4 (de) *	2005-03-19	2008-05-07	Se Young Chung	Verfahren zur herstellung eines extrakts für die vorbeugung bzw. behandlung von hypolipidämie und fettleibigkeit aus dem extrakt des oberirdischen teils von aster spathulifolius, und diesen enthaltende zusammensetzung
WO2012138214A1 (en) *	2011-04-08	2012-10-11	Brewster Lizzy Maritza	Beta-guanidinopropionic acid for the treatment of hypertension
SG10201702809XA (en) *	2012-10-18	2017-05-30	Nissin Foods Holdings Co Ltd	Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method
EP4072561A4 (de) *	2019-12-11	2023-11-29	Inspirna, Inc.	Verfahren zur behandlung von krebs
CN113598232A (zh) *	2021-07-05	2021-11-05	安徽科技学院	一种非发酵凝固型甜酒风味奶及其生产方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1195199A (en) *	1966-11-25	1970-06-17	Horlicks Pharmaceuticals Ltd	Improvements in Compositions comprising Insulin.
GB1195200A (en) *	1967-02-07	1970-06-17	Horlicks Pharmaceuticals Ltd	Pharmaceutical Compositions.
US3843798A (en) *	1973-03-12	1974-10-22	Stanley Drug Products Inc	Methods and compositions for inducing resistance to bacterial infections
GB1552179A (en) *	1976-11-02	1979-09-12	Beecham Group Ltd	Pharmaceutical compositions for treating hyperglycaemia
US5053420A (en) *	1989-10-13	1991-10-01	Pershadsingh Harrihar A	Thiazolidine derivatives for the treatment of hypertension
IT1237519B (it) *	1989-11-27	1993-06-08		Impiego dell'acido guanidinacetico per indurre un incremento del contenuto muscolare di creatina
GB9003185D0 (en) *	1990-02-13	1990-04-11	Ici Plc	Pharmaceutical compositions
AU7316591A (en) *	1990-02-28	1991-09-18	Upjohn Company, The	Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

1992
- 1992-08-19 EP EP92918163A patent/EP0601001B1/de not_active Expired - Lifetime
- 1992-08-19 AU AU24794/92A patent/AU2479492A/en not_active Abandoned
- 1992-08-19 JP JP5504419A patent/JPH06510286A/ja active Pending
- 1992-08-19 US US08/196,250 patent/US5900435A/en not_active Expired - Fee Related
- 1992-08-19 WO PCT/US1992/006776 patent/WO1993003724A1/en not_active Ceased
- 1992-08-19 DE DE69219136T patent/DE69219136T2/de not_active Expired - Fee Related
- 1992-08-19 AT AT92918163T patent/ATE151634T1/de not_active IP Right Cessation
- 1992-08-19 ES ES92918163T patent/ES2101866T3/es not_active Expired - Lifetime
- 1992-08-19 DK DK92918163.4T patent/DK0601001T3/da active
1997
- 1997-06-19 GR GR970401487T patent/GR3023848T3/el unknown

Also Published As

Publication number	Publication date
GR3023848T3 (en)	1997-09-30
EP0601001A1 (de)	1994-06-15
ES2101866T3 (es)	1997-07-16
AU2479492A (en)	1993-03-16
EP0601001B1 (de)	1997-04-16
WO1993003724A1 (en)	1993-03-04
US5900435A (en)	1999-05-04
DE69219136T2 (de)	1997-08-28
DK0601001T3 (da)	1997-10-20
DE69219136D1 (de)	1997-05-22
JPH06510286A (ja)	1994-11-17

Legal Events

Date	Code	Title	Description
1997-10-15	UEP	Publication of translation of european patent specification
2003-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69219136D1 (de)	1997-05-22	Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
Heller	2004	Weight gain during insulin therapy in patients with type 2 diabetes mellitus
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
HUP0002373A2 (hu)	2000-10-28	Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
UY26425A1 (es)	2001-07-31	Formulación y método antidiabético
JPS61148121A (ja)	1986-07-05	治療用組成物
Astwood et al.	1946	Treatment of hyperthyroidism with propylthiouracil
ATE290863T1 (de)	2005-04-15	Verwendung von prolactinmodulatoren und diät zur herstellung eines medikamentes zur behandlung der fettleibigkeit
HU9401369D0 (en)	1994-08-29	Human il-4 mutant proteins, thats containing pharmaceutical product and process for producing of proteins
Wechsler	1940	Recovery in amyotrophic lateral sclerosis: treated with tocopherols (vitamin E): preliminary report
Jordan et al.	1974	Hunger and satiety in humans during parenteral hyperalimentation
DK0764632T3 (da)	2001-09-24	Selektive beta3-adrenerge agonister
McNeil et al.	1984	Domestic metallic mercury poisoning
US3928578A (en)	1975-12-23	Composition for control of white muscle disease
Maxeiner et al.	1997	Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries
RU94012067A (ru)	1997-03-20	Средство для лечения осложнений инсулинзависимого и инсулиннезависимого сахарного диабета
Tan et al.	1996	Pharmacologic treatment options for non-insulin-dependent diabetes mellitus
ATE143947T1 (de)	1996-10-15	N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
Kaplan et al.	1970	Thyroid as an adjuvant to amphetamine therapy of obesity. A controlled double-blind study
Walter	1973	Clinical impressions on treatment of obsessional states with intravenous clomipramine (Anafranil)
Ostern et al.	1965	Hypertension following Ornade ingestion
Mirtallo et al.	1980	Albumin in TPN solutions: potential savings from a prospective review
US6270756B1 (en)	2001-08-07	Weight loss induced by alpha interferon and gamma interferon
US3565560A (en)	1971-02-23	Pharmaceutical preparation containing hydrofuramide and method of using it
US3449499A (en)	1969-06-10	Method for the reduction of glycemia